

**Appendix B**

Clean copy of claims pending

1           1. (Amended) A conjugate comprising a drug coupled with an isolated peptide  
2           sequence selected from the group consisting of SEQ ID Nos. 1-8.

1           2. (Amended) The conjugate of claim 1, said isolated peptide sequence having  
2           from 4-30 amino acid residues.

1           6. The conjugate of claim 1, said drug selected from a class of drugs consisting of  
2           anti-inflammatory agents, antitumor agent, oligonucleotides, cytokines, enzyme  
3           inhibitors, and vasoregulator agents.

1           7. The conjugate of claim 1 said drug selected from the group consisting of  
2           methotrexate, lovastatin, taxol, ajmalicine, vinblastine, vincristine, cyclophosphamide,  
3           fluorouracil, idarubicin, ifosfamide, irinotecan, 6-mercaptopurine, mytomyins,  
4           mitoxantrone, paclitaxel, taxol, pentostatin, plicamycin, topotecan, fludarabine,  
5           etoposide, doxorubicin, doxorubicin, danorubicin, albuterol, and propidium.

1           8. The conjugate of claim 1, said drug being methotrexate.

1           9. (Amended) The conjugate of claim 1, said isolated peptide sequence having at  
2           least about 50% homology with at least one of said SEQ ID Nos. 1-8.

1           35. The conjugate of claim 1, said conjugate characterized by the ability of  
2           binding to surface receptors of target cells and subsequently being internalized by said  
3           target cells.

1           37. (Amended) The conjugate of claim 1, wherein the a drug is coupled with an  
2 isolated peptide sequence of SEQ ID NO. 8. wherein the peptide sequence further  
3 comprises penicillamine.

1           38. The conjugate of claim 1, said isolated peptide sequence being cyclic.

1           42. A conjugate comprising a first portion and a second portion, wherein said first  
2 portion is a peptide and said second portion is a drug, said peptide being derived from  
3 ICAM-1 or LFA-1 and being characterized by binding to LFA-1 and ICAM-1 receptors  
4 on leudocytes and by being internalized by cells expressing at least one of said receptors.